The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.
Researchers linked disrupted circadian rhythms to brain volume loss and elevated dementia risk, identifying the hippocampus and thalamus as key brain regions affected by irregular sleep-wake patterns.
Patients with atypical Alzheimer’s variants had shorter survival and faced a 31% higher mortality risk than those with typical forms, according to a study of over 2,000 biomarker-confirmed cases.
Researchers tracked suicidal behavior in early schizophrenia and found four distinct patterns linked to depression, delayed treatment, and childhood trauma.
A large UK-based cohort study found that early menopause—before age 40—is associated with both higher depressive symptoms and worse cognitive function over time.
Researchers analyzed medical records of over 2500 Alzheimer’s patients and found most comorbidities, like hypertension and hyperlipidemia, began before diagnosis—except for depression, which was diagnosed afterward.
Researchers analyzed over 10,000 adults and found that individuals with panic disorder reported more severe alcohol and tobacco use, especially among men, with no significant differences across racial groups.
Inhibiting a protein called hnRNP A1 disrupted myelin repair in mouse brains without causing noticeable behavioral changes, according to a new study exploring its effects across multiple brain regions.